Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

Aptose Biosciences Inc.

CIK 882361 APTOF·Biological Products · All EDGAR filings ↗

Material weakness Filing comparison

Aptose Biosciences Inc. reported internal control effective again after a material weakness

Material weakness in internal control Internal control reported effective

The weakness was first reported on 2025-05-08 — 370 days and 3 annual reports before this one.

As of March 31, 2026, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013 Framework). Based on this assessment, our management concluded that, as of March 31, 2026, our internal control over financial reporting was effective based on those criteria. We are a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K…
Evidence
Current state
effective
Current state label
Internal control reported effective
Direction
remediated
Prior filed
2025-11-13
Prior form
10-Q
Prior state
material_weakness
Prior state label
Material weakness in internal control
Remediation stated
No
Severity
normal
Source
Item 9A internal control conclusion, compared with the prior filing
Weakness annual reports
3
Weakness days reported
370
Weakness first reported
2025-05-08
Why
The company's conclusion on internal control over financial reporting changed: a material weakness was newly reported, or a previously reported one no longer appears.